Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.65 |
| ▸ | PLK1 | P53350 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | AKT1 | P31749 | 1/20 | 0.57 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31394873 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KCNH2MEN1KMT2AEPHX1 | |
| SCHEMBL23496704 | 0.84 | EPHX1 (0.64) | ALDH1A1KCNH2MEN1KMT2AEPHX1 | |
| SCHEMBL30479195 | 0.84 | EPHX1 (0.64) | ALDH1A1KCNH2MEN1KMT2AEPHX1 | |
| SCHEMBL3662241 | 0.84 | EPHX1 (0.67) | ALDH1A1KCNH2EPHX1PLK1NPC1 | |
| SCHEMBL24092944 | 0.82 | EPHX1 (0.76) | ALDH1A1KCNH2MEN1KMT2AEPHX1 | |
| SCHEMBL18340971 | 0.82 | EPHX1 (0.65) | ALDH1A1KCNH2EPHX1PLK1SMN1; SMN2 | |
| SCHEMBL17891689 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KCNH2MEN1KMT2AEPHX1 | |
| SCHEMBL11162636 | 0.81 | ALDH1A1 (0.67) | ALDH1A1KCNH2MEN1KMT2AEPHX1 | |
| SCHEMBL3050543 | 0.81 | EPHX1 (0.69) | ALDH1A1MEN1KMT2AEPHX1PLK1 | |
| SCHEMBL14096446 | 0.79 | ALDH1A1 (0.69) | ALDH1A1KCNH2MEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-3313828-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016206101-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016210234-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227331-B2 | Metallo-β-lactamase inhibitors | ALPI, GAA, ZFX | ALDH1A1 310/4885KCNH2 1651/4885MEN1 711/4885 |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ALPI, GAA, ZFX | ALDH1A1 319/4885KCNH2 1620/4885MEN1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.